anti-Fc Receptor-Like 4 (FCRL4) Antibodies

Human Fc Receptor-Like 4 (FCRL4) interaction partners

1. Abs with reactivity to commensal microbiota were enriched in FCRL4(+) cells.

2. We conclude that these activated B cells are a component of the local autoimmune response, and through their RANKL expression, can contribute to joint destruction. Furthermore, their expression of FcRL4 and their enrichment in the IgA isotype points towards a potential role for these cells in the link between mucosal and joint inflammation.

3. intraepithelial FcRL4(+) B-cells are present in the salivary glands of pSS patients. These cells are likely involved in the epithelial changes seen in pSS. Their enrichment in parotid glands may explain why MALT lymphomas in pSS patients preferentially develop at this specific location.

4. Commercially available IRTA1 antibody can immunohistochemically distinguish MALT lymphoma from other low-grade B-cell lymphomas.

5. decreased FCRL4 expression and association of FCRL2 expression with inflammatory markers and disease activity suggested the contribution of these molecules to rheumatoid arthritis inflammatory processes.

6. Significantly increased FCRL4 mRNA only in Graves disease patients but not in Hashimoto patients compared to normal controls.

7. The observed significant gene-environment interaction suggests that drinking and cooking oil use with FCRL4 gene polymorphism has a significant interaction.

8. we provide evidence for involvement of HCK and FGR in FCRL4-mediated immunoregulation and for the functional importance of posttranslational modifications of the FCRL4 molecule.

9. IRTA1 and T-bet are positive markers for the diagnosis of nodal marginal zone lymphoma

10. Data indicate that signaling by HIV-1 gp120 through integrin alpha4beta7 resulted in increased expression of the immunosuppressive cytokine TGF-beta1 and FcRL4.

11. The cytological features, growth pattern and IRTA1 positivity in nodal marginal zone lymphomas suggest they may derive from IRTA1(+) perifollicular B cells or monocytoid B cells detectable in reactive lymph nodes.

12. The FCRL4 polymorphisms may play an important role in the susceptibility and severity of ankylosing spondylitis in the Chinese Han population.

13. In cellular binding assays, as a bona fide receptor FcRL4 binds efficiently to immunoglobulin (Ig)A.

14. Data suggest that expression of FcRL4 in B-cells results in inhibition of BCR signaling at point of Syk phosphorylation by mechanism that involves phosphorylation of FcRL4 and its association with SHP-1/SHP-2.

15. Characterization and comparison of the structure and B-cell expression pattern of the entire family of IRTA genes, which includes 5 members contiguously located on chromosome.

16. role of IRTA1 in the immune function of B cells within epithelia

17. Monocytoid B cells differ in their antigen profile (presence of IRTA1) from splenic and nodal marginal zone B cells.

18. Cell surface expression of this immunoregulatory molecule is restricted to a subpopulation of memory B cells.

19. Fc receptor-like 1-5 molecules are similarly expressed in progressive and indolent clinical subtypes of B-cell chronic lymphocytic leukemia.

20. Down-regulation of FCRL4 is associated with acute lymphoblastic leukemia.